The adjuvanted recombinant nanoparticle-based vaccine GBP510/AS03 shows a clinically acceptable safety profile and immunogenicity results comparable to that of the currently available ChAdOx1-S ...
The COVID-19 pandemic, caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in December 2019. Since then, extensive efforts have been made to develop and evaluate ...
In a recent study posted to the medRxiv* pre-print server, researchers evaluated the immunogenicity of booster doses of alum-adjuvanted SCB-2019 vaccine candidate's three formulations. They tested ...
A recent eClinicalMedicine study evaluated the safety and efficacy of the GBP510 vaccine, which contains self-assembling nanoparticles, against severe acute respiratory syndrome coronavirus-2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results